Cantor Fitzgerald set a $103.00 price objective on Spark Therapeutics (NASDAQ:ONCE) in a research report sent to investors on Friday, September 21st. The firm currently has a buy rating on the biotechnology company’s stock.

Several other brokerages also recently issued reports on ONCE. ValuEngine downgraded shares of Spark Therapeutics from a buy rating to a hold rating in a research report on Wednesday, August 8th. UBS Group cut their price objective on shares of Spark Therapeutics from $80.00 to $53.00 and set a neutral rating for the company in a research report on Wednesday, August 8th. Raymond James set a $82.00 price objective on shares of Spark Therapeutics and gave the stock a buy rating in a research report on Wednesday, August 8th. Mizuho restated a buy rating and set a $77.00 price objective on shares of Spark Therapeutics in a research report on Wednesday, August 8th. Finally, Leerink Swann restated a market perform rating and set a $55.00 price objective (down from $74.00) on shares of Spark Therapeutics in a research report on Tuesday, August 7th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. Spark Therapeutics has a consensus rating of Hold and an average price target of $70.10.

NASDAQ:ONCE traded up $1.15 during mid-day trading on Friday, hitting $47.94. The stock had a trading volume of 424,681 shares, compared to its average volume of 653,823. Spark Therapeutics has a twelve month low of $41.06 and a twelve month high of $96.59. The company has a market capitalization of $2.05 billion, a P/E ratio of -6.28 and a beta of 2.24.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.34). The firm had revenue of $25.19 million during the quarter, compared to analyst estimates of $29.44 million. Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%. Equities research analysts anticipate that Spark Therapeutics will post -1.36 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its holdings in shares of Spark Therapeutics by 90.9% during the first quarter. PNC Financial Services Group Inc. now owns 2,100 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 1,000 shares during the period. Aperio Group LLC increased its holdings in shares of Spark Therapeutics by 23.5% during the second quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock worth $459,000 after purchasing an additional 1,056 shares during the period. Tocqueville Asset Management L.P. increased its holdings in shares of Spark Therapeutics by 2.7% during the second quarter. Tocqueville Asset Management L.P. now owns 41,225 shares of the biotechnology company’s stock worth $3,412,000 after purchasing an additional 1,075 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Spark Therapeutics by 2.1% during the first quarter. New York State Common Retirement Fund now owns 52,787 shares of the biotechnology company’s stock worth $3,515,000 after purchasing an additional 1,100 shares during the period. Finally, Amalgamated Bank increased its holdings in shares of Spark Therapeutics by 29.7% during the second quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 1,100 shares during the period.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Read More: How Investors Use a Balance Sheet

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.